ChromaTan Awarded $2.5 million FDA Contract
September 22, 2017
ChromaTan has been awarded a $2.5 million contract from the FDA to fund the development of a new continuous purification platform for the production of monoclonal antibodies (mAbs) using its Continuous Countercurrent Tangential Chromatography (CCTC™) technology.
You can read the story from GEN here
Or, visit the ChromaTan website for more information.
Congratulations to the ChromaTan team!